Removal and Inactivation of Hepatitis A Virus during Manufacture of Urokinase from Human Urine
![]() |
Kim, In-Seop
(Central Research Center, Green Cross Plasma Derivatives Company)
Park, Yong-Woon (Central Research Center, Green Cross Plasma Derivatives Company) Lee, Sung-Rae (Central Research Center, Green Cross Plasma Derivatives Company) Yong Kang (Central Research Center, Green Cross Plasma Derivatives Company) Lee, Kyung-Myung (Department of Production, Green Cross Biotech Company) Park, Dae-Han (Department of Production, Green Cross Biotech Company) Woo, Han-Sang (Central Research Center, Green Cross Plasma Derivatives Company) Lee, Soungmin (Central Research Center, Green Cross Plasma Derivatives Company) |
1 |
Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin.
/
|
2 |
Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation.
/
과학기술학회마을 |
3 |
Viral clearance strategies for biopharmaceutical safety: Part 1. General considerations.
/
|
4 |
Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
/
DOI ScienceOn |
5 |
Virus removal by filtration.
/
|
6 |
Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization.
/
|
7 |
Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate.
/
과학기술학회마을 |
8 |
Inactivation kinetics of model and relevant bloodborne viruses by treatment with sodium hydroxide and heat
/
DOI ScienceOn |
9 |
Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability.
/
|
10 |
Enhanced virus removal by flocculation and microfiltration.
/
과학기술학회마을 DOI |
11 |
(2001) Removal and inactivation of viruses during hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter.
/
DOI ScienceOn |
12 |
Strategies to produce virus-safe blood derivatives.
/
|
13 |
The use of a microporus polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins.
/
DOI ScienceOn |
14 |
Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter.
/
DOI ScienceOn |
15 |
Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma.
/
과학기술학회마을 |
16 |
Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma.
/
과학기술학회마을 |
17 |
Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV.
/
DOI ScienceOn |
18 |
Thrombolytic therapy in acute myocardial infarction. A perspective.
/
|
19 |
Efficient removal of viruses by a novel polyvinylidene fluoride membrane filter.
/
DOI ScienceOn |
20 |
Detection of hepatitis A virus in the feces of patients with naturally acquired infections.
/
DOI ScienceOn |
21 |
Foundling viruses and transfusion medicine.
/
DOI ScienceOn |
22 |
Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma.
/
과학기술학회마을 DOI ScienceOn |
23 |
Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
/
DOI ScienceOn |
24 |
Andrewes’ Viruses of Vertebrates
/
|
25 |
Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma.
/
과학기술학회마을 |
26 |
/
|
27 |
Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance.
/
|
28 |
Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates.
/
|
![]() |